BrightSpring Health Services, Inc. BTSG revenue by segment, product and geography
In its fiscal year ending 2025-12-31, BrightSpring Health Services, Inc. reported revenue across 2 business segments; the largest, Pharmacy Solutions, was $11.4B, 88.7% of the filed sum (+30.7% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Pharmacy Solutions$11.4B88.7%+30.7% yoy
- Provider Services$1.46B11.3%+11.1% yoy
Members sum to the consolidated $12.9B for this period.
- Product$11.4Bshare n/a+30.7% yoy
- Medicare D$4.1Bshare n/a+28.0% yoy
- Commercial Insurance$3.3Bshare n/a+30.7% yoy
- Medicare C$2.41Bshare n/a+44.9% yoy
- Medicaid$1.5Bshare n/a+28.2% yoy
- Service$1.46Bshare n/a+11.1% yoy
- Medicare A$1.09Bshare n/a+9.5% yoy
- Private And Other$424Mshare n/a+2.2% yoy
- +1 more member in the filing
member sum exceeds the consolidated figure: this axis carries more than one breakdown, so shares are not computed.
- Pharmacy Solutions$3.41B88.0%+22.1% yoy
- Provider Services$466M12.0%+30.3% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.